Unknown Manufacturer
Tadekinig alfa is under investigation in clinical trial NCT03113760 (Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency).
Tadekinig alfa is under investigation in clinical trial NCT03113760 (Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency).
